Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 83-96 , March 2006

Clinical use of plasma and plasma fractions

  • Richard K. Spence, MD, FACS (Chairman)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 410 368 2712; Fax: +1 410 951 4007.

References 

  1. Beloeil H, Brosseau M, Benhamou D. [Transfusion of fresh frozen plasma (FFP): audit of prescriptions]. Ann Fr Anesth Reanim. 2001;20(8):686–692
  2. Ozier Y, Pessione F, Samain E, et al. Institutional variability in transfusion practice for liver transplantation. Anesth Analg. 2003;97(3):671–679
  3. Covin R, O'Brien M, Grunwald G, et al. Factors affecting transfusion of fresh frozen plasma, platelets, and red blood cells during elective coronary artery bypass graft surgery. Arch Pathol Lab Med. 2003;127(4):415–423
  4. Circular of Information, A.a.A. AABB, Editor, 2002.
  5. Kakaiya RM, Morse EE, Panek S. Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang. 1984;46(1):44–46
  6. Novis DA, Renner S, Friedberg RC, et al. Quality indicators of fresh frozen plasma and platelet utilization. Arch Pathol Lab Med. 2002;126(5):527–532
  7. Solheim BG, Flesland O, Brosstad F, et al. Improved preservation of coagulation factors after pre-storage leukocyte depletion of whole blood. Transfus Apheresis Sci. 2003;29(2):133–139
  8. Hoots WK, Abrams C, Tankersley D. The food and drug administration's perspective on plasma safety. Transfus Med Rev. 2001;15(2 supplement 1):20–26
  9. Williamson LM, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang. 1995;69(3):159–165
  10. Fischer G, Hoots WK, Abrams C. Viral reduction techniques: types and purpose. Transfus Med Rev. 2001;15(2 supplement 1):27–39
  11. Hilfenhaus J, Groner A, Nowak T, Weimer T. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion. 1997;37(9):935–940
  12. Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 1998;74(supplement 1):219–223
  13. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res. 2002;107(supplement 1):S3–S8
  14. Wieding JU, Hellstern P, Kohler M. Inactivation of viruses in fresh-frozen plasma. Ann Hematol. 1993;67(6):259–266
  15. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis. 2003;14(3):283–287
  16. Suontaka AM, Blomback M, Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion. 2003;43(5):568–575
  17. Beck KH, Mortelsmans Y, Kretschmer VV, et al. Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed. 2000;27(3):144–148
  18. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272(15):1210–1214
  19. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest. 2004;126(1):249–258
  20. Popovsky MA, Haley NR. Further characterization of transfusion-related acute lung injury: demographics, clinical and laboratory features, and morbidity. Immunohematology. 2001;17(4):157–159
  21. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for the clinical use of plasma. Thromb Res. 2002;107(supplement 1):S53–S57
  22. Gunter P. Practice guidelines for blood component therapy. Anesthesiology. 1996;85(5):1219–1220
  23. Lepatan LM, Hernandez FG, Montoya MM, et al. Cryoprecipitate-removed plasma ‘cryo-removed plasma’ as a source of factor IX in the treatment of haemophilia B. Haemophilia. 2004;10(3):254–258
  24. Pantanowitz L, Kruskall MS, Uhl L. Cryoprecipitate. Patterns of use. Am J Clin Pathol. 2003;119(6):874–881
  25. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001;29(7 supplement):S90–S94
  26. Hack CE. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27(6):633–638
  27. Levi M, de Jonge E, van der Poll T, ten Cate H. Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med. 2000;28(9 supplement):S20–S24
  28. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Crit Care Med. 2000;28(9 supplement):S38–S43
  29. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000;28(9 supplement):S31–S33
  30. de Jonge E, van der Poll T, Kesecioglu J, Levi M. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. Semin Thromb Hemost. 2001;27(6):667–674
  31. Freeman BD, Buchman TG. Coagulation inhibitors in the treatment of sepsis. Expert Opin Investig Drugs. 2002;11(1):69–74
  32. Hewson JR. Homeostatic alterations with major trauma. Massive transfusion. Can Anaesth Soc J. 1985;32(3 Pt 1):239–240
  33. Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost. 1988;14(4):299–338
  34. Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg. 1979;190(1):91–99
  35. Freeman JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang. 1998;74(supplement 1):225–229
  36. Jabbour N, Gagandeep S, Mateo R, et al. Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg. 2004;240(2):350–357
  37. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001;94(5):773–781discussion 5A–6A
  38. Ledgerwood AM, Lucas CE. A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile. J Trauma. 2003;54(5):S68–S74
  39. Vazquez Rodriguez JJ, Ortiz Vazquez J, Martin Herrera L, Pozo J. [Moschowitz's thrombocytopenic thrombotic purpura]. Rev Clin Esp. 1969;112(2):147–160
  40. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program). 2004;407–423
  41. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol. 2004;41(1):4–14
  42. Yarranton H, Machin SJ. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura. Curr Opin Neurol. 2003;16(3):367–373
  43. Fontana S, Hovinga JA, Studt JD, et al. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol. 2004;41(1):48–59
  44. McCarthy LJ, Dlott JS, Orazi A, et al. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial. 2004;8(2):80–86
  45. Hwang WY, Chai LY, Ng HJ, et al. Therapeutic plasmapheresis for the treatment of the thrombotic thrombocytopenic purpura–haemolytic uraemic syndromes. Singapore Med J. 2004;45(5):219–223
  46. Shamseddine A, Saliba T, Aoun E, et al. Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. J Clin Apheresis. 2004;19(3):119–124
  47. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol. 2004;
  48. Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. Curr Opin Hematol. 2002;9(5):389–394
  49. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 2003;1(4):625–631
  50. Knovich MA, Craver K, Matulis MD, et al. Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma. Am J Hematol. 2004;76(3):286–290
  51. McCarthy LJ. Evidence-based medicine for apheresis: an ongoing challenge. Ther Apher Dial. 2004;8(2):112–123
  52. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11–28
  53. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med. 2003;24(4):607–622
  54. Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2(7985):542–545
  55. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39(11–12):1227–1234
  56. Youssef WI, Salazar F, Dasarathy S, et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98(6):1391–1394
  57. French CJ, Bellomo R, Angus P. Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care. 2003;31(4):357–361
  58. Muntean W. Fresh frozen plasma in the pediatric age group and in congenital coagulation factor deficiency. Thromb Res. 2002;107(supplement 1):S29–S32
  59. The Northern Neonatal Nursing Initiative [NNNI] Trial Group . A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. Eur J Pediatr. 1996;155(7):580–588
  60. McCall MM, Blackwell MM, Smyre JT, et al. Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. Ann Thorac Surg. 2004;77(3):983–987discussion 987
  61. Oliver WC, Beynen FM, Nuttall GA, et al. Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thorac Surg. 2003;75(5):1506–1512
  62. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126(1):139–152
  63. Roberts I, Alderson P, Bunn F, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2004;4:CD000567
  64. Bunn F, Alderson P, Hawkins V. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2003;1:CD001319
  65. Bunn F, Lefebvre C, Li Wan Po A, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. The albumin reviewers. Cochrane Database Syst Rev. 2000;2:CD001208
  66. Guven M, Sungur M, Eser B, et al. The effects of fresh frozen plasma on cholinesterase levels and outcomes in patients with organophosphate poisoning. J Toxicol Clin Toxicol. 2004;42(5):617–623
  67. Eder AF, Manno CS. Does red-cell T activation matter?. Br J Haematol. 2001;114(1):25–30

PII: S1521-6926(05)00049-6

doi: 10.1016/j.beha.2005.01.035

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 83-96 , March 2006

Article Tools